UBE2D2: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: UBE2D2

NCBI ID: G7322

UBE2D2

UBE2D2: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The inability to manage persistent pain can significantly impact an individual's quality of life and overall well-being. As such, there is a growing interest in identifying new treatments and biomarkers for chronic pain. In this article, we focus on UBE2D2, a protein that has been identified as a potential drug target and biomarker for chronic pain.

The UBE2D2 enzyme

UBE2D2 is a protein that is expressed in various tissues, including the brain, skeletal muscles, and organs. It is a member of the ubiquitin-conjugating enzyme family 2 (UBE2D2) and has a molecular weight of approximately 29 kDa. UBE2D2 plays a critical role in the regulation of protein degradation and has been implicated in a number of cellular processes, including cell signaling, tissue repair, and inflammation.

In recent years, researchers have identified UBE2D2 as a potential drug target for chronic pain. One of the key reasons for this is the high levels of UBE2D2 expression in the brain, which is known to play a role in the regulation of pain signaling. Additionally, UBE2D2 has been shown to interact with a number of other proteins that are involved in pain signaling, including the neurotransmitter GABA. This suggests that UBE2D2 may be a useful target for the development of drugs that can alleviate chronic pain.

UBE2D2 as a biomarker

In addition to its potential as a drug target, UBE2D2 has also been identified as a potential biomarker for chronic pain. One of the key advantages of using UBE2D2 as a biomarker is that it is highly expressed in a variety of tissues and cells, including pain-related tissues such as the brain and muscle. This makes it a potential diagnostic tool for chronic pain, as it can be used to monitor the effectiveness of pain treatments.

UBE2D2 has also been shown to be involved in the regulation of pain signaling in the brain. It has been shown to interact with the neurotransmitter GABA, which is involved in the regulation of pain signaling. Additionally, UBE2D2 has been shown to play a role in the regulation of neurotransmitter release from pain-related neurons. This suggests that UBE2D2 may be involved in the neural mechanisms that underlie chronic pain.

The potential implications of UBE2D2 as a biomarker for chronic pain are significant. If UBE2D2 is shown to be involved in the regulation of pain signaling in the brain, it suggests that it may be a useful target for the development of drugs that can alleviate chronic pain. Additionally, if UBE2D2 is used as a biomarker for tracking the effectiveness of pain treatments, it can help to improve the accuracy and effectiveness of pain assessments.

UBE2D2 as a drug target

The potential use of UBE2D2 as a drug target for chronic pain is based on the high levels of UBE2D2 expression in pain-related tissues and the fact that it has been shown to interact with the neurotransmitter GABA. By targeting UBE2D2 with small molecules or other compounds, it may be possible to alleviate chronic pain.

One of the key challenges in developing drugs that target UBE2D2 is the need to identify compounds that are specific to this protein. This is because UBE2D2 is expressed in a variety of tissues and cells, including those that are not involved in pain signaling. To address this challenge, researchers have used a variety of techniques, including high-throughput screening and bioinformatics analysis, to identify compounds that are specific to UBE2D2.

So far, the most promising compounds that have been identified as UBE2D2 inhibitors come from a variety of different chemical families, including compounds that are derived from natural products, such as herbal compounds, and compounds that are derived from the DNA of bacteria. These compounds have been shown to block

Protein Name: Ubiquitin Conjugating Enzyme E2 D2

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-linked polyubiquitination. Mediates the selective degradation of short-lived and abnormal proteins. Functions in the E6/E6-AP-induced ubiquitination of p53/TP53. Mediates ubiquitination of PEX5 and autoubiquitination of STUB1 and TRAF6. Involved in the signal-induced conjugation and subsequent degradation of NFKBIA, FBXW2-mediated GCM1 ubiquitination and degradation, MDM2-dependent degradation of p53/TP53 and the activation of MAVS in the mitochondria by RIGI in response to viral infection. Essential for viral activation of IRF3

The "UBE2D2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2D2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets